Company Analysis
Sign in

Ionis Pharmaceuticals, Inc. (IONS)

Nasdaq: IONS · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.9
◀ Past 6.0● Present 5.9▶ Future 5.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,325 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ionis Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
1,325
1,321 utility, 4 reissue, 1976 to Dec 31, 2025
Granted in 2025
18
Against 17 in 2024 and 25 in 2023
Applications published
1,230
42 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals79
Biotechnology30
Organic fine chemistry12
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Isis Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in CA, printed in SO)
1,050 granted
715 published
Ionis Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
275 granted
417 published
Ionis Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
85 published
ISIS PHARMACEUTICALS, INC. a former name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
13 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,684Compositions and methods for modulating apolipoprotein C-III expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
Dec 23, 202512,502,402Compounds and methods for modulating GFAPPharmaceuticalsIonis Pharmaceuticals, Inc.
Dec 16, 202512,496,311Methods for safely reducing thrombopoietinPharmaceuticalsIonis Pharmaceuticals, Inc.
Nov 25, 202512,480,126Modulation of dystrophia myotonica-protein kinase (DMPK) expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
Sep 9, 202512,410,430Modulating apolipoprotein (A) expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
Sep 9, 202512,409,188Modulators of HSD17B13 expressionBiotechnologyIonis Pharmaceuticals, Inc.
Aug 12, 202512,384,814Compounds and methods for reducing app expressionBiotechnologyIonis Pharmaceuticals, Inc.
Jul 8, 202512,350,285Compounds and methods for reducing ATXN3 expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
Jul 1, 202512,343,357Compositions and methods for modulating MECP2 expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
May 13, 202512,297,431Modulation of huntingtin expressionPharmaceuticalsIonis Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376683Selective Antisense Compounds and Uses ThereofBiotechnologyIonis Pharmaceuticals, Inc.
Dec 4, 20252025/0368995Linkage Modified Oligomeric Compounds and Uses ThereofPharmaceuticalsIonis Pharmaceuticals, Inc.
Dec 4, 20252025/0368993Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofBiotechnologyIonis Pharmaceuticals, Inc.
Nov 20, 20252025/0354147Antisense Compounds Targeted to CLN3 and Uses ThereofPharmaceuticalsIonis Pharmaceuticals, Inc.
Nov 20, 20252025/0354135Modified Compounds and Uses ThereofBiotechnologyIonis Pharmaceuticals, Inc.
Nov 20, 20252025/0353873COMPOUNDS AND METHODS FOR MODULATING APOE EXPRESSIONOrganic fine chemistryIonis Pharmaceuticals, Inc.
Nov 13, 20252025/0346907COMPOUNDS AND METHODS FOR REDUCING GLYCOGEN SYNTHASE 1BiotechnologyIonis Pharmaceuticals, Inc.
Nov 13, 20252025/0346899CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEPharmaceuticalsIonis Pharmaceuticals, Inc.
Nov 13, 20252025/0346898Linkage Modified Oligomeric Compounds and Uses ThereofBiotechnologyIonis Pharmaceuticals, Inc.
Nov 6, 20252025/0340888COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSIONPharmaceuticalsIonis Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 58 · Biotechnology 34 · Organic fine chemistry 7 · Chemical engineering 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IONS · research, not advice